Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

NCT04469855 · Completed

Last updated 2026-05-28

This study tracks the safety of the diabetes medication Ozempic® in adults with type 2 diabetes over a long-term period by monitoring any side effects that occur.

Status Completed The study has finished.

Type Observational

Participants 3,217 people

Who can join all sexes

Timeline Started 2020-07 · est. completion 2025-05

Where 414 sites · Japan

What this study is testing ClinicalTrials.gov NCT04469855 ↗

Description as written by the study sponsor.

The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years. People above the age of 18 will be asked to fill in the quality of life (QOL) questionnaire (the QOL questionnaire is for the assessment of the influence of diabetes treatment on people's life). There is a possibility that people's blood sample would be provided to Novo Nordisk from their doctors in case of severe allergic reaction that might be caused by Ozempic®.

Treatments tested

semaglutide Drug

Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.

Main thing measured	Number of adverse events (AEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04469855 ↗